Manager × security

Versant Venture Management, LLC CRSP holdings history

Who else holds this security? →

CRISPR THERAPEUTICS AG · CUSIP H17182108 · CIK 1560009

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Versant Venture Management, LLC reported 148.83K CRSP (shares), valued at $8.12M, or 4.99% of its reported non-derivative portfolio. Filed 2026-08-12.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
4.99%
Shares
148.83K
148,831
Reported value
$8.12M
USD

Shares unchanged; reported value increased 14.65%, and weight changed -0.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20264.99%148,831SEC filing ↗Filed Aug 12, 2026
Q1 20265.01%148,831SEC filing ↗Filed May 5, 2026
Q4 20255.17%148,831SEC filing ↗Filed Feb 12, 2026
Q3 20254.54%148,831SEC filing ↗Filed Nov 10, 2025
Q2 202529.52%498,558SEC filing ↗Filed Aug 11, 2025
Q1 202528.18%498,558SEC filing ↗Filed May 7, 2025
Q4 202422.62%498,558SEC filing ↗Filed Feb 12, 2025
Q3 202436.84%498,558SEC filing ↗Filed Nov 8, 2024
Q2 202434.84%498,558SEC filing ↗Filed Aug 7, 2024
Q1 202432.95%498,558SEC filing ↗Filed May 3, 2024
Q4 20238.03%498,558SEC filing ↗Filed Feb 8, 2024
Q3 202312.03%498,558SEC filing ↗Filed Nov 3, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 202312.03%498,558$22.63MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 3, 2023
Q4 20238.03%498,558$31.21MShares unchanged; reported value increased 37.92%, and weight changed -4.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 8, 2024
Q1 202432.95%498,558$33.98MShares unchanged; reported value increased 8.88%, and weight changed +24.92 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 3, 2024
Q2 202434.84%498,558$26.93MShares unchanged; reported value decreased 20.76%, and weight changed +1.89 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 7, 2024
Q3 202436.84%498,558$23.42MShares unchanged; reported value decreased 13.02%, and weight changed +2.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 8, 2024
Q4 202422.62%498,558$19.62MShares unchanged; reported value decreased 16.22%, and weight changed -14.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2025
Q1 202528.18%498,558$16.97MShares unchanged; reported value decreased 13.54%, and weight changed +5.56 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 7, 2025
Q2 202529.52%498,558$24.25MShares unchanged; reported value increased 42.93%, and weight changed +1.34 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 11, 2025
Q3 20254.54%148,831$9.65MShares decreased 70.15%; reported value decreased 60.22%, and weight changed -24.98 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 10, 2025
Q4 20255.17%148,831$7.80MShares unchanged; reported value decreased 19.09%, and weight changed +0.63 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2026
Q1 20265.01%148,831$7.08MShares unchanged; reported value decreased 9.29%, and weight changed -0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 5, 2026
Q2 20264.99%148,831$8.12MShares unchanged; reported value increased 14.65%, and weight changed -0.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2026
Versant Venture Management, LLC · CRISPR THERAPEUTICS AG

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1560009","quarter":"2026Q2","cusip":"H17182108"}

get_institutional_manager_history
{"cik":"1560009","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.